WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter BlumejensenPresident and CEO2026-02-2114,265$1.53
$21.83kSell
Katharine PetersonChief Accounting Officer2026-02-14116$1.63
$189.08Sell
Mary MillerChief Legal Officer2026-02-14217$1.63
$353.71Sell
Peter BlumejensenPresident and CEO2026-02-141,302$1.63
$2.12kSell
Erick GamelinChief Development Officer2026-02-14471$1.63
$767.73Sell
Eric DevroeChief Operating Officer2026-02-14723$1.63
$1.18kSell
Peter BlumejensenPresident and CEO2026-02-14579$1.63
$943.77Sell
Mary MillerChief Legal Officer2026-01-17659$1.98
$1.30kSell
Adam D. LevyChief Financial Officer2026-01-148,832$1.70
$15.00kBuy
Peter BlumejensenPresident and CEO2026-01-1449,000$1.68
$82.12kBuy

1 of 5

ACRV insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP21.53%8,340,508$13.68MInstitution
Chione Ltd9.93%3,848,632$6.31MInsider
Kristina Masson9.53%3,691,232$6.05MInsider
Perceptive Advisors LLC8.01%3,104,139$5.09MInsider
Peter Blumejensen6.94%2,688,329$4.41MInsider
Sands Capital Alternatives LLC5.48%2,122,605$3.48MInstitution
Citadel Advisors LLC4.24%1,641,884$2.69MInstitution
Wellington Management Group LLP2.29%888,130$1.46MInstitution
Wellington Biomedical Innovation Master Investors Cayman I LP2.29%888,130$1.46MInsider
Vanguard Group Inc1.80%698,857$1.15MInstitution

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV48.03%38.25%Net SellingNet Selling
IMA31.32%68.68%Net Buying
OKUR27.34%72.66%Net SellingNet Selling
CING4.41%37.95%Net BuyingNet Buying
GRCE27.97%45.52%
View Top Biotech Stocks

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 48.03% institutional shareholders, 38.25% Acrivon Therapeutics insiders, and 13.71% retail investors. Chione Ltd is the largest individual Acrivon Therapeutics shareholder, owning 3.85M shares representing 9.93% of the company. Chione Ltd's Acrivon Therapeutics shares are currently valued at $6.31M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.